Umeå University's logo

umu.sePublications
EnglishSvenskaNorsk
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A novel biosignature to assess residual risk in ductal carcinoma in situ (DCIS) patients after standard treatment
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences.ORCID iD: 0000-0003-0571-7265
Show others and affiliations
2020 (English)In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 38, no 15, p. 548-548Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
American Society of Clinical Oncology , 2020. Vol. 38, no 15, p. 548-548
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-176093DOI: 10.1200/JCO.2020.38.15_suppl.548ISI: 000560368300057OAI: oai:DiVA.org:umu-176093DiVA, id: diva2:1501518
Available from: 2020-11-17 Created: 2020-11-17 Last updated: 2020-11-17Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records

Wadsten, Charlotta

Search in DiVA

By author/editor
Wadsten, Charlotta
By organisation
Department of Surgical and Perioperative Sciences
In the same journal
Journal of Clinical Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 115 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
v. 2.47.0
|
WCAG
|
Log in
|
Manuals
|
Contact the Library